News

At the new facility, the company will produce both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market. Located in Technopark Grabtsevo in the Kaluga

The company’s US unit Eisai employs about 1,800 people and its operations include research and development, manufacturing, sales and marketing and administrative functions. Eisai chairman and CEO Yuji

The company’s lead compound, cabozantinib, inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. Currently, cabozantinib is being evaluated in an ongoing Phase III METEOR

The deal is part of Cipla’s front-end strategy and will expedite its product registrations in Brazil. Subject to certain closing deliverables, the transaction is expected to be completed

The trial showed that WM patients treated with Imbruvica experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of

Development of the LIMITX is currently being supported by a grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to develop an

If approved, lifitegrast has the potential to be the first treatment indicated to address both signs and symptoms of the disease. Lifitegrast is a new small-molecule integrin inhibitor

Relamorelin is Rhythm’s Phase II ghrelin agonist being developed for the treatment of diabetic gastroparesis and gastrointestinal (GI) functional disorders. Ghrelin is a peptide hormone produced in the

TCON is focused on the development and commercialization of new targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The agreement strengthens intellectual property estate around TRC102